Financial_NNP summary_NN Growth_NN 2005_CD 2004_CD m_NN m_NN CER_NNP %_NN %_NN Turnover_NN 21,660_CD 19,986_CD 7_CD 8_CD Operating_NN profit_NN 6,874_CD 5,756_CD 16_CD 19_CD profit_NN before_IN taxation_NN 6,732_CD 5,779_CD 13_CD 16_CD profit_NN after_IN taxation_NN for_IN the_DT year_NN 4,816_CD 4,022_CD 17_CD 20_CD profit_NN attributable_JJ to_TO minority_NN interests_NNS 127_CD 114_CD profit_NN attributable_JJ to_TO shareholders_NNS 4,689_CD 3,908_CD Earnings_NNS per_IN share_NN 82.6_CD p_VBP 68.1_CD p_JJ 18_CD 21_CD Diluted_VBN earnings_NNS per_IN share_NN 82.0_CD p_NN 68.0_CD p_NN Dividends_NNS per_IN share_NN 44p_CD 42p_CD Net_JJ cash_NN inow_NN from_IN operating_VBG activities_NNS 5,958_CD 4,944_CD Net_JJ assets_NNS 7,570_CD 5,937_CD History_NN and_CC development_NN of_IN the_DT company_NN GlaxoSmithKline_NNP plc_NN is_VBZ a_DT public_JJ limited_JJ company_NN incorporated_VBN on_IN 6th_JJ December_NNP 1999_CD under_IN English_JJ law_NN ._.
Its_PRP$ shares_NNS are_VBP listed_VBN on_IN the_DT London_NNP Stock_NNP Exchange_NNP and_CC the_DT New_NNP York_NNP Stock_NNP Exchange_NNP ._.
On_IN 27th_JJ December_NNP 2000_CD the_DT company_NN acquired_VBD Glaxo_NNP Wellcome_NNP plc_NN and_CC SmithKline_NNP Beecham_NNP plc_NN ,_, both_DT English_JJ public_JJ limited_JJ companies_NNS ,_, by_IN way_NN of_IN a_DT scheme_NN of_IN arrangement_NN for_IN the_DT merger_NN of_IN the_DT two_CD companies_NNS ._.
Both_DT Glaxo_NNP Wellcome_NNP and_CC SmithKline_NNP Beecham_NNP were_VBD major_JJ global_JJ healthcare_NN businesses_NNS ._.
GSK_NNP plc_NN and_CC its_PRP$ subsidiary_NN and_CC associated_VBN undertakings_NNS constitute_VBP a_DT major_JJ global_JJ healthcare_NN group_NN engaged_VBD in_IN the_DT creation_NN ,_, discovery_NN ,_, development_NN ,_, manufacture_NN and_CC marketing_NN of_IN pharmaceutical_JJ and_CC consumer_NN health-related_JJ products_NNS ._.
GSK_NNP has_VBZ its_PRP$ corporate_JJ head_NN ofce_NN in_IN London_NNP ._.
It_PRP also_RB has_VBZ operational_JJ headquarters_NN in_IN Philadelphia_NNP and_CC Research_NNP Triangle_NNP Park_NNP ,_, USA_NNP ,_, and_CC operations_NNS in_IN some_DT 119_CD countries_NNS ,_, with_IN products_NNS sold_VBN in_IN over_IN 130_CD countries_NNS ._.
The_DT principal_JJ research_NN and_CC development_NN R&D_NNP facilities_NNS are_VBP in_IN the_DT UK_NNP ,_, the_DT USA_NNP ,_, Japan_NNP ,_, Italy_NNP ,_, Spain_NNP and_CC Belgium_NNP ._.
Products_NNPS are_VBP currently_RB manufactured_VBN in_IN some_DT 37_CD countries_NNS ._.
The_DT major_JJ markets_NNS for_IN the_DT Groups_NNS products_NNS are_VBP the_DT USA_NNP ,_, France_NNP ,_, Japan_NNP ,_, the_DT UK_NNP ,_, Italy_NNP ,_, Germany_NNP and_CC Spain_NNP ._.
Business_NNP segments_NNS GSK_NNP operates_VBZ principally_RB in_IN two_CD industry_NN segments_NNS :_: Pharmaceuticals_NNP prescription_NN pharmaceuticals_NNS and_CC vaccines_NNS Consumer_NNP Healthcare_NNP over-the-counter_JJ medicines_NNS ,_, oral_JJ care_NN and_CC nutritional_JJ healthcare_NN ._.
The_DT Group_NNP ,_, as_IN a_DT multinational_JJ business_NN ,_, operates_VBZ in_IN many_JJ countries_NNS and_CC earns_VBZ revenues_NNS and_CC incurs_VBZ costs_NNS in_IN many_JJ currencies_NNS ._.
The_DT results_NNS of_IN the_DT Group_NNP ,_, as_IN reported_VBN in_IN sterling_NN ,_, are_VBP therefore_RB affected_VBN by_IN movements_NNS in_IN exchange_NN rates_NNS between_IN sterling_NN and_CC overseas_JJ currencies_NNS ._.
Average_JJ exchange_NN rates_NNS prevailing_VBG during_IN the_DT period_NN are_VBP used_VBN to_TO translate_VB the_DT results_NNS and_CC cash_NN ows_NNS of_IN overseas_JJ subsidiary_NN and_CC associated_VBN undertakings_NNS and_CC joint_JJ ventures_NNS into_IN sterling_NN ._.
Period_NN end_NN rates_NNS are_VBP used_VBN to_TO translate_VB the_DT net_JJ assets_NNS of_IN those_DT undertakings_NNS ._.
The_DT currencies_NNS which_WDT most_RBS inuence_JJ these_DT translations_NNS are_VBP the_DT US_NNP dollar_NN ,_, the_DT Euro_NNP and_CC the_DT Japanese_JJ Yen_NN ._.
In_IN order_NN to_TO illustrate_VB underlying_VBG performance_NN ,_, it_PRP is_VBZ the_DT Groups_NNS practice_NN to_TO discuss_VB its_PRP$ results_NNS in_IN terms_NNS of_IN constant_JJ exchange_NN rate_NN CER_NNP growth_NN ._.
This_DT represents_VBZ growth_NN calculated_VBN as_IN if_IN the_DT exchange_NN rates_NNS used_VBN to_TO determine_VB the_DT results_NNS of_IN overseas_JJ companies_NNS in_IN sterling_NN had_VBD remained_VBN unchanged_JJ from_IN those_DT used_VBN in_IN the_DT previous_JJ year_NN ._.
CER_CD %_NN represents_VBZ growth_NN at_IN constant_JJ exchange_NN rates_NNS ._.
%_NN represents_VBZ growth_NN at_IN actual_JJ exchange_NN rates_NNS ._.
Cautionary_JJ statement_NN regarding_VBG forward-looking_JJ statements_NNS The_DT Group_NNP 's_POS reports_NNS led_VBD with_IN or_CC furnished_VBN to_TO the_DT US_NNP Securities_NNPS and_CC Exchange_NNP Commission_NNP SEC_NNP ,_, including_VBG this_DT document_NN and_CC written_VBN information_NN released_VBN ,_, or_CC oral_JJ statements_NNS made_VBN ,_, to_TO the_DT public_NN in_IN the_DT future_NN by_IN or_CC on_IN behalf_NN of_IN the_DT Group_NNP ,_, may_MD contain_VB forward-looking_JJ statements_NNS ._.
Forward-looking_VBG statements_NNS give_VBP the_DT Group_NNP 's_POS current_JJ expectations_NNS or_CC forecasts_NNS of_IN future_JJ events_NNS ._.
An_DT investor_NN can_MD identify_VB these_DT statements_NNS by_IN the_DT fact_NN that_IN they_PRP do_VBP not_RB relate_VB strictly_RB to_TO historical_JJ or_CC current_JJ facts_NNS ._.
They_PRP use_VBP words_NNS such_JJ as_IN anticipate_VBP ,_, estimate_VBP ,_, expect_VBP ,_, intend_VBP ,_, will_MD ,_, project_NN ,_, plan_NN ,_, believe_VB and_CC other_JJ words_NNS and_CC terms_NNS of_IN similar_JJ meaning_NN in_IN connection_NN with_IN any_DT discussion_NN of_IN future_JJ operating_NN or_CC financial_JJ performance_NN ._.
In_IN particular_JJ ,_, these_DT include_VBP statements_NNS relating_VBG to_TO future_JJ actions_NNS ,_, prospective_JJ products_NNS or_CC product_NN approvals_NNS ,_, future_JJ performance_NN or_CC results_NNS of_IN current_JJ and_CC anticipated_JJ products_NNS ,_, sales_NNS efforts_NNS ,_, expenses_NNS ,_, the_DT outcome_NN of_IN contingencies_NNS such_JJ as_IN legal_JJ proceedings_NNS ,_, and_CC financial_JJ results_NNS ._.
The_DT Group_NNP undertakes_VBZ no_DT obligation_NN to_TO update_VB any_DT forward-looking_JJ statements_NNS ,_, whether_IN as_IN a_DT result_NN of_IN new_JJ information_NN ,_, future_JJ events_NNS or_CC otherwise_RB ._.
Forward-looking_VBG statements_NNS involve_VBP inherent_JJ risks_NNS and_CC uncertainties_NNS ._.
The_DT Group_NNP cautions_VBZ investors_NNS that_IN a_DT number_NN of_IN important_JJ factors_NNS ,_, including_VBG those_DT in_IN this_DT document_NN ,_, could_MD cause_VB actual_JJ results_NNS to_TO differ_VB materially_RB from_IN those_DT contained_VBN in_IN any_DT forward-looking_JJ statement_NN ._.
Such_JJ factors_NNS include_VBP ,_, but_CC are_VBP not_RB limited_VBN to_TO ,_, those_DT discussed_VBN under_IN Risk_NNP factors_NNS on_IN pages_NNS 71_CD to_TO 74_CD of_IN this_DT Annual_JJ Report_NNP ._.
GSK_NNP Annual_JJ Report_NNP 2005_CD 04_CD REPORT_NNP OF_IN THE_DT DIRECTORS_NNS
